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is similar for males and females. Growing inequality generally increases GMS cover-
age but pushes some persons aged over 70 above the qualifying income threshold. 
Repeating 2010 average income in 2011 would increase the 2011 GMS medicines 
cost by around € 110m; repeating the 2010 inequality changes would increase it by 
a further € 105m, ceteris paribus. ConClusions: Fiscal cutbacks during recession 
induce countervailing increases in the medical card population and the public cost 
of its medicines. These are the first systematic and detailed estimates – by age, 
gender and region – of whose medical access is affected and how much the offset-
ting public cost will increase.
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objeCtives: About 52.6% or 125,434 people of the population in Burgenland is 
physical inactive. As a risk factor for several chronic diseases like cardiovascular 
diseases, type 2 diabetes, osteoporosis, depression, back-pain, hypertension, breast 
cancer and colorectal carcinoma physical inactivity can potentially be a substantial 
public health burden. Furthermore, it is one of the greatest risk factors for global 
mortality. Hence, the aim of the analysis was to estimate the direct health-care costs 
saved, the number of diseases and premature death saved each year attributable to 
a health promotion program focusing on walking (“3,000 steps” more). Methods: 
The evaluation of the health-economic impact was performed using a cost-of-illness 
analysis. We have used relative risk (RR) estimates from the literature to evaluate 
the effects of physical inactivity on the above mentioned diseases. Afterwards, the 
population-attributable fraction (PAF) for each illness to estimate the risk factor on 
the given disease was computed. Direct medical costs were considered from the 
health care system perspective. Costs were calculated bottom-up for the year 2012. 
We have calculated effects of a reduction in inactivity level by 10,000 physical inac-
tive people in Burgenland. Results: Results show that physical inactivity causes 
27,542 cases of illness as well as 50 premature deaths in population of Burgenland, 
leading to a total cost-of-illness of 58.9 million Euro (6.3% of total health expendi-
ture). Reducing the inactive group by 10,000 people, 2,221 cases of illness and cases 
of death will be reduced by four. Moreover the cost of illness could be reduced by 
6.40 million Euro each year of which 5.03 million Euro are directly related to dimin-
ish physical inactivity. ConClusions: Physical inactivity represents an important 
public health burden in Austria. Even modest reductions in inactivity levels could 
result in substantial cost savings.
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objeCtives: The modified reference price procedure, which was introduced 
in October 2011, caused significant savings in the Health Insurance Fund’s 
Pharmaceutical budget. In our analysis we aim to give an insight into the effects 
of this measure on the drug consumption and on the sales of the pharmaceutical 
companies as well as measure the generated savings and losses on the side of the 
industry. In the course of the analysis we examine the change in the demand of 
the related drugs and in their composition, from the aspect of industry, financer 
and patients. We explore which are the price strategies of the companies and are 
they managed to increase the sales or decrease the losses with them. The proper 
knowledge of the effects of blind bid will support the decision making of the con-
cerned market actors as well as the further rulemaking. Methods: A retrospec-
tive data analysis was conducted on the official NHIFA (national Health Insurance 
Fund) monthly data-base between October 2011 and March 2013. Results: In 
the blind bid procedure 90 companies, 169 active substances and more than 2100 
product were involved. The relevant products market share is almost 30% of the 
total Hungarian Pharmaceutical budget, which is almost 1 billion € annually. 
As we found, the blind bid process has a significant saving effect for the 
financer. The cumulative savings on the 18 months period reached 113 millions 
€ for the financer. It means 24% reduction on the average reimbursement level, 
whilst the average manufacturer price decreased 16% and a minimal 3% savings 
was realized on the co-payment side. ConClusions: Huge savings were real-
ized with this new reference pricing method, where the financer realized the 
most of the savings.
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objeCtives: Older people (> 70) with high risk of future health problems discharged 
from acute medical units (AMU) within 72 hours, in Nottingham and Leicester, 
England, were included in an RCT of an interface geriatric intervention (IGI) compris-
ing geriatrician assessment and further specialist management. The objective was 
to assess cost-effectiveness of IGI compared to standard care. Methods: In the 
trial-based economic evaluation, 417 participants (IGI: 205) were analysed at 90-day 
follow-up. Health (inpatient, day-case, outpatient), social care and IGI resource-use 
data were collected and combined with unit costs to estimate total cost. Quality-
adjusted life years (QALY), based on EQ-5D valuations at baseline and follow-up, 
were obtained for 254 (60.9%) participants. Multiple imputation by chained equa-
tions was applied to deal with missing QALY values. Cost and QALYs were adjusted 
by baseline characteristics using regression methods, and probabilistic incremental 
cost-effectiveness ratios (ICER) were constructed. Sub-group analysis was carried 
demographic factors underlying the cost of GMS prescribing in Ireland are complex 
and inter-related. Alternative solutions to the question GMS coverage in the elderly 
may need to be found soon that prove fiscally and economically sustainable. The 
large gap in GMS prescribing costs between men and women in early adulthood 
requires further investigation.
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objeCtives: Cost-effectiveness analyses play a key role in the reimbursement of 
health care technologies and require health care resource use (HRU) cost inputs. 
Inaccuracies in inputs can lead to potentially significant differences in results. Thus, 
the availability of HRU costs is vital for decision-making. This study’s objective is to 
assess the transparency and ease of access to HRU costs in France, Germany, Italy, 
Spain and the UK. Methods: A targeted search and contact with country-specific 
representatives highlighted existing national documentation. A cross-sectional 
selection of costs were searched for including GP and nurse costs; hospital bed and 
overhead costs; drug prices; follow-up/out-patient visit costs; and the availability of 
Diagnosis-Related Group (DRG) codes and tariffs. The transparency and availability 
of costs were assessed using the following criteria: the date, access restrictions and 
the need for assumptions to generate cost estimates. Results: DRG tariffs were 
identified for all countries, but the availability of other data varied. Drug prices were 
obtainable online (such as the website MedicPrix, France), but others required paid 
registration (Giofil, Italy). The UK had the most accessible primary and secondary 
care HRU cost data through PSSRU. Italy was the least transparent however AIFA 
informed us a website reform will increase access to data in 2014. Where not explicit, 
HRU costs can be indirectly derived from total procedure codes (for example through 
ATIH, France). Spain and Italy’s regional structure made sourcing national cost data 
challenging, resulting in wide ranges in input costs in published cost-effectiveness 
analyses. ConClusions: Whilst some nations provided transparent HRU cost data, 
others did not, causing inconsistent inputs across cost-effectiveness analyses. To 
minimise inconsistency we propose a hierarchy of evidence for use when sourc-
ing costs: 1) Govt/health service official sources; 2) Official international websites 
(OECD/WHO); 3) Published economic studies; 4) Published non-economic studies; 
5) National expert opinion; and 6) Unofficial websites/sources.
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objeCtives: Standard approaches to economic evaluations based on cost utility 
analysis are increasingly considered inadequate. While simple and intuitive, it is 
acknowledged that the QALY alone does not capture all aspects of health benefit. 
Multi Criteria Decision Analysis (MCDA) has been proposed as a way of incorporat-
ing multiple factors influencing the value of a health technology. The objective of 
this study was to analyse past reimbursement recommendations by the National 
Centre for Pharmacoeconomics (NCPE) in Ireland in order to identify factors which 
have influenced decisions in the past. Methods: Based on published literature, 
national guidelines and experience, a list of potentially influencing criteria was 
identified. Information on each criterion was extracted for each full pharmacoeco-
nomic assessment conducted by the NCPE. Logistic regression was used to estimate 
the impact each of these criteria has had on past recommendations. Model fit was 
assessed using the Deviance Information Criterion and the best fit model was cho-
sen using backwards stepwise regression. Results: Between 2006 and May 2013 the 
NCPE conducted 54 full pharmacoeconomic assessments. Each of these was scored 
against 14 criteria, which can be grouped into clinical utility, consumer demand, 
economic incentives, societal perspective and efficiency/affordability. The model 
of choice identified criteria of each group which impact on reimbursement recom-
mendations. ConClusions: This analysis shows that factors other than cost per 
QALY have impacted on past valuations of health technologies in Ireland. Since the 
analysis was carried out retrospectively, these factors have influenced decisions in 
an informal manner and do not necessary represent the factors which should influ-
ence future reimbursement decisions. This approach contrasts with methods used 
elsewhere to estimate weights for the criteria. The results of this analysis provide 
a basis for the development of a MCDA approach to HTA in Ireland, which has the 
potential to improve consistent and transparent decision making.
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objeCtives: To model the age, gender and regional pattern of GMS coverage rates 
as they are key determinants of public spending on GMS medicines. Methods: 
We used PCRS (Primary Care Reimbursement Service) and CSO (Central Statistics 
Office) databases to estimate GMS coverage rates by age, gender and region in 2010 
and 2011. Assuming log-normally distributed incomes we used CSO SILC data to 
estimate GMS coverage semi-elasticities in 2010. We estimated how much GMS 
male and female coverage rates in 7 adult age categories and 8 Irish regions in 
2010 responded to changing average income levels, income inequality and income 
thresholds. We tracked how well our predicted GMS coverage rates fitted actual 
rates in 2011. We simulated the 2011 GMS medicines cost burden of a ceteris 
paribus repeat of the 2010 changes in income and income-inequality. Results: 
Our modelled coverage rates have high goodness of fit compared to conventional 
econometric estimates. Coverage income-semi-elasticity ranges from .7 to 2.3, is 
highest for elderly age cohorts and in the South-East and South-West regions and 
